Joshua M. Eizen - 05 Nov 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
06 Nov 2026, 18:20:03 UTC
Prior SEC filing
10 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Filing notes and source

Key filing fact

Joshua M. Eizen filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 06 Nov 2026.

Key facts

  • This page summarizes Joshua M. Eizen's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 06 Nov 2026, 18:20.

Change

  • Previous filing in this sequence was filed on 10 Jul 2026.
  • Current net transaction value: -$11,926.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001949621 Primary reporting owner

Eizen Joshua M

Relationship
Chief Operating Officer and Chief Legal Officer
Address
C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Signature date
06 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANTX transaction

Common Stock

Sale

Transaction value
-$11,926
Shares
-2,826
Change %
-1.3%
Price
$4.22
Shares after
207,546
Date
05 Nov 2026
Ownership
Direct
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2026.

Footnote F2

Includes a balance of (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (c) 58,500 RSUs which vest as follows 1/4th of the RSUs vest annually over four years from January 1, 2025 and (d) 50,000 RSUs which vest as follows: 1/4th of RSUs vest annually over four years from January 1, 2026, in each case subject to the Reporting Person's continuous service as of such date.

Footnote F3

Reflects the adjusted total which includes the purchase of 3,818 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.

SEC remarks

Chief Operating Officer and Chief Legal Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .